Sunday, February 8, 2026
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Breaking News

Gates Announces Secondary Offering and Share Repurchase Program

Elaine Mendonca by Elaine Mendonca
February 13, 2024
in Breaking News
0
Technology Cloud computing
0
SHARES
6
VIEWS
Share on FacebookShare on Twitter

On February 13, 2024, Gates Industrial Corporation plc (NYSE:GTES), widely recognized as Gates, made a significant announcement regarding a secondary offering. The offering entails the sale of 17,500,000 ordinary shares by certain selling stockholders affiliated with Blackstone Inc. This exciting opportunity also includes a provision that grants underwriters a 30-day option to purchase an additional 2,625,000 ordinary shares.

The selling of these shares can take place in various avenues, including the New York Stock Exchange, the over-the-counter market, negotiated transactions, or any other method that aligns with market prices or negotiated prices. The offering is expected to conclude on February 16, 2024, pending customary closing conditions. It is important to note that Gates will not be participating in this offering and will not receive any proceeds from the sale of shares.

Citigroup, Goldman Sachs & Co. LLC, and Jefferies have been appointed as the joint lead book-running managers for this offering. Additionally, Barclays, Morgan Stanley, UBS Investment Bank, BMO Capital Markets, Evercore ISI, Mizuho, and RBC Capital Markets will also serve as joint book-running managers. This collaboration among esteemed financial institutions highlights the significance of this offering.

In conjunction with its existing share repurchase strategy, Gates has also unveiled a share repurchase program. This program demonstrates the company’s commitment to enhancing shareholder value and further strengthens their position in the market.

GTES Stock Analysis: Price Decrease and Trading Range Overview – February 13, 2024

On February 13, 2024, GTES stock opened at $12.53, which was $0.27 lower than its previous close. The stock experienced a price decrease of $0.10 since the market last closed, representing a drop of 0.74%. Trading in the middle of its 52-week range suggests that GTES has not reached any extreme highs or lows within the past year. Additionally, being above its 200-day simple moving average is generally considered a positive sign. While a decrease of $0.10 may seem insignificant, it is worth noting that even small price movements can have a significant impact, especially for investors with large positions. However, it is crucial to remember that stock prices are influenced by various factors, and further research and analysis should be conducted to evaluate GTES’s financial health, growth prospects, and any recent developments that may have influenced its stock price. Investors should consult with a financial advisor or conduct thorough research before making any investment decisions.

GTES Stock Performance: Mixed Results with Fluctuating Net Income and Stable Revenue

On February 13, 2024, GTES stock performance showcased a mixed picture. Despite holding flat in terms of total revenue since the previous year and quarter, the company experienced a slight increase in net income compared to the previous year, but a decrease from the previous quarter. Earnings per share (EPS) also saw positive growth from the previous year but remained unchanged from the previous quarter.

GTES reported $3.57 billion in total revenue in the past year and $863.30 million in the fourth quarter. The company’s total revenue remained flat compared to the previous year and quarter.

GTES recorded $233.50 million in net income in the past year and $63.00 million in the fourth quarter. Net income increased by approximately 5.56% compared to the previous year but decreased by 20.05% compared to the previous quarter.

GTES reported $0.85 in earnings per share (EPS) in the past year and $0.24 in the fourth quarter. EPS increased by approximately 10.13% compared to the previous year but remained unchanged from the previous quarter.

Overall, GTES’s stock performance on February 13, 2024, showcased a mixed bag of results. While total revenue held steady, net income experienced fluctuations, and EPS showed positive growth but remained unchanged from the previous quarter. Investors and analysts may monitor GTES closely to evaluate the reasons behind the fluctuating net income and its potential impact on the company’s future performance.

Tags: GTES
Elaine Mendonca

Elaine Mendonca

Related Posts

NFT projects
Breaking News

The Impact of TikToks Fate on USChina Relations and American Tech Giants

March 16, 2024
Businesses finance
Breaking News

Blackstone Strategic Credit 2027 Term Fund BGB Announces Monthly Dividend of 93 Cents per Share

March 15, 2024
Healthcare-sector
Breaking News

Analyzing Short Interest in Molina Healthcare Inc MOH

March 15, 2024
Next Post
The Rise of Enterprise Business Intelligence Platforms: Transforming Operations in the Healthcare Sector

BIOLASE Inc Announces Details of Public Offering

Healthcare Services Stock Exchange

InMode Reports Strong Financial Performance and Market Reaction

Biochemistry and biomedicines

JetBlue Airways Stock Soars Amidst Carl Icahns Investment and Merger Controversy

Recommended

FCBC stock news

Impax Asset Management Group plc Reduces Stake in Snap Inc. as Insiders Sell Off Shares

2 years ago
The Trade Desk Stock

The Trade Desk: A Market Conundrum of Conflicting Signals

3 months ago
Intel Stock

US Government Holds Massive Intel Share Position, Creating Market Uncertainty

5 months ago
Nuvalent Stock

Nuvalent Shares Surge on Promising Clinical Trial Results

3 months ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Newsletter
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple ASML BioNTech Bitcoin Broadcom Coca-Cola Coinbase D-Wave Quantum Eli Lilly Fiserv IBM Intel Kraft Heinz Marvell Technology META Micron Microsoft MP Materials MSCI World ETF Newmont Mining NIO Novo Nordisk Nvidia Ocugen Opendoor Oracle Palantir PayPal Plug Power QuantumScape Robinhood Rocket Lab USA Strategy Super Micro Computer Synopsys Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics
No Result
View All Result

Highlights

Tax Clarity and Sector Optimism Bolster Outlook for Chicago Atlantic

RBB Bancorp Reports Strong Asset Quality Improvement and Strategic Capital Review

Cassava Sciences Confirms Alzheimer Drug Failure and Faces Regulatory Delays

DroneShield Shares Face Headwinds Despite Record Performance

Rock Tech Lithium: Investors Await the Final Go-Ahead

Puma Biotechnology Sets Date for Full-Year Financial Disclosure

Trending

KemPharm Stock
Analysis

Zevra Therapeutics Advances Rare Disease Portfolio with New Data and Strategic Expansion

by Kennethcix
February 8, 2026
0

Zevra Therapeutics continues to build its profile as a dedicated rare disease company. Recent clinical data presentations...

Oak Valley Stock

Oak Valley Bancorp Surpasses $2 Billion Milestone with Record Annual Profit

February 8, 2026
SuRo Capital Stock

SuRo Capital Sharpens Focus on AI Infrastructure Investments

February 8, 2026
Chicago Atlantic Real Estate Finance Stock

Tax Clarity and Sector Optimism Bolster Outlook for Chicago Atlantic

February 8, 2026
RBB Stock

RBB Bancorp Reports Strong Asset Quality Improvement and Strategic Capital Review

February 8, 2026

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • Zevra Therapeutics Advances Rare Disease Portfolio with New Data and Strategic Expansion
  • Oak Valley Bancorp Surpasses $2 Billion Milestone with Record Annual Profit
  • SuRo Capital Sharpens Focus on AI Infrastructure Investments

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com